在成本效益分析中使用健康实用性:对物质使用障碍的系统审查
Anh Dam Tran1, Xin Zhan2, Annaëlle Vinzent3
1National Drug and Alcohol Research Centre, University of New South Wales, Kensington, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia.
The International journal on drug policy
|October 10, 2024
概括
对物质使用障碍 (SUD) 的成本效益分析 (CUA) 往往缺乏对健康效益措施的证明. 使用健康实用应用工具 (HAT) 可以提高SUD干预措施的经济评估的可靠性.
科学领域:
- 卫生经济学 卫生经济学
- 药物使用障碍 药物使用障碍
- 卫生技术评估 卫生技术评估
背景情况:
- 成本效益分析 (CUA) 对于评估药物使用障碍 (SUD) 的干预措施至关重要.
- 评估健康公用事业措施在SUD模拟的CUA中的适用性对于可靠的经济评估至关重要.
- 之前的研究强调了在SUD经济评估中应用卫生实用措施的变化.
研究的目的:
- 确定和审查在试验内和模拟的物质使用障碍 (SUD) 的成本效益分析 (CUA).
- 评估用于SUD的模拟CUA中使用的健康实用措施的适用性.
- 提供建议,以提高SUD经济评估的质量.
主要方法:
- 在多个数据库 (Medline,Embase,EconLit,PBAC) 进行了系统的文献搜索.
- 描述了针对SUD干预的已识别的CUA研究,重点关注健康效用测量.
- 卫生实用应用工具 (HAT) 用于在模拟的CUA.中审查卫生实用的适用性.
主要成果:
- 包括49项CUA研究 (14项在试验内,35项模拟).
- 在试验内CUA中,EQ-5D-5L是常见的,而在模拟CUA中使用了标准博,EQ-5D-5L和SF-6D.
- 许多模拟CUA研究缺乏对生活质量指标,价值组和适用性评估的详细描述.
结论:
- 在SUD的模拟CUA中,医疗实用选择的理由经常缺失.
- 建议使用健康实用应用工具 (HAT) 来加强对健康实用性的评估.
- 提高经济评估的可靠性将有助于决策者在SUD干预方面做出明智的决策.
更多相关视频
相关概念视频
Substance Use Disorders Affecting Sleep
161
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
161
Drug Dependence
983
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
983
Drug Abuse and Addiction: Pharmacological Phenomena
447
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
447
Stress and Mental Health
81
Chronic stress profoundly affects mental health, significantly influencing mood, behavior, and overall quality of life. Research closely links chronic stress with mental health conditions such as depression, anxiety, and substance use disorders. Ongoing exposure to stress can lead to physiological and psychological changes, initiating a cycle of emotional distress and maladaptive coping mechanisms.
Individuals with depression often experience challenges in both their personal and professional...
Individuals with depression often experience challenges in both their personal and professional...
81
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
Drug Control Governance: Regulatory Bodies and Their Impact
144
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
144


